WallStreetZenWallStreetZen

NASDAQ: ALLO
Allogene Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALLO

Based on 4 analysts offering 12 month price targets for Allogene Therapeutics Inc

Min Forecast
$5.00+126.24%
Avg Forecast
$8.75+295.93%
Max Forecast
$14.00+533.48%

Should I buy or sell ALLO stock?

Based on 4 analysts offering ratings for Allogene Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALLO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ALLO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ALLO stock forecasts and price targets.

ALLO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2026-01-09
lockedlocked$00.00+00.00%2026-01-07

1 of 1

Forecast return on equity

Is ALLO forecast to generate an efficient return?

Company
7.37%
Industry
68.5%
Market
178.91%
ALLO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALLO forecast to generate an efficient return on assets?

Company
5.18%
Industry
31.48%
ALLO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALLO earnings per share forecast

What is ALLO's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
-$0.89
Avg 2 year Forecast
-$0.82
Avg 3 year Forecast
-$0.72

ALLO revenue forecast

What is ALLO's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$18.5k
Avg 2 year Forecast
$26.2M
Avg 3 year Forecast
$154.5M

ALLO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALLO$2.21$8.75+295.93%Strong Buy
ZVRA$9.15$23.67+158.66%Strong Buy
PROK$1.79$12.00+570.39%Buy
YDES$7.73N/AN/A
VALN$6.42N/AN/A
View Top Biotech Stocks

Allogene Therapeutics Stock Forecast FAQ

Is Allogene Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ALLO) stock is to Strong Buy ALLO stock.

Out of 4 analysts, 3 (75%) are recommending ALLO as a Strong Buy, 1 (25%) are recommending ALLO as a Buy, 0 (0%) are recommending ALLO as a Hold, 0 (0%) are recommending ALLO as a Sell, and 0 (0%) are recommending ALLO as a Strong Sell.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.

What is ALLO's earnings growth forecast for 2026-2028?

(NASDAQ: ALLO) Allogene Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.77%.

Allogene Therapeutics's earnings in 2026 is -$190,886,000.On average, 18 Wall Street analysts forecast ALLO's earnings for 2026 to be -$216,694,193, with the lowest ALLO earnings forecast at -$351,186,472, and the highest ALLO earnings forecast at -$110,065,731. On average, 16 Wall Street analysts forecast ALLO's earnings for 2027 to be -$200,263,561, with the lowest ALLO earnings forecast at -$360,742,566, and the highest ALLO earnings forecast at -$71,670,708.

In 2028, ALLO is forecast to generate -$175,715,125 in earnings, with the lowest earnings forecast at -$267,570,645 and the highest earnings forecast at -$125,423,740.

What is ALLO's revenue growth forecast for 2026-2028?

(NASDAQ: ALLO) Allogene Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.29%.

Allogene Therapeutics's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast ALLO's revenue for 2026 to be $4,520,618, with the lowest ALLO revenue forecast at $0, and the highest ALLO revenue forecast at $25,596,682. On average, 12 Wall Street analysts forecast ALLO's revenue for 2027 to be $6,375,280,164, with the lowest ALLO revenue forecast at $0, and the highest ALLO revenue forecast at $35,888,985,382.

In 2028, ALLO is forecast to generate $37,666,126,419 in revenue, with the lowest revenue forecast at $4,539,144,870 and the highest revenue forecast at $110,760,497,952.

What is ALLO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ALLO) forecast ROA is 5.18%, which is lower than the forecast US Biotechnology industry average of 31.48%.

What is ALLO's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ALLO price target, the average ALLO price target is $8.75, with the highest ALLO stock price forecast at $14.00 and the lowest ALLO stock price forecast at $5.00.

On average, Wall Street analysts predict that Allogene Therapeutics's share price could reach $8.75 by Mar 13, 2027. The average Allogene Therapeutics stock price prediction forecasts a potential upside of 295.93% from the current ALLO share price of $2.21.

What is ALLO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ALLO) Allogene Therapeutics's current Earnings Per Share (EPS) is -$0.87. On average, analysts forecast that ALLO's EPS will be -$0.89 for 2026, with the lowest EPS forecast at -$1.44, and the highest EPS forecast at -$0.45. On average, analysts forecast that ALLO's EPS will be -$0.82 for 2027, with the lowest EPS forecast at -$1.48, and the highest EPS forecast at -$0.29. In 2028, ALLO's EPS is forecast to hit -$0.72 (min: -$1.10, max: -$0.51).

What is ALLO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ALLO) forecast ROE is 7.37%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.